RxDoctor Payments Data

Barabara Kinkle, PA

Physician Assistant · Redlands, CANPI 1104262757

Payments from drug & device makers

$6,474in general payments, 2019–2025

Across 482 payments — averaging $13.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • AbbVie$1K
  • Lilly USA, LLC$530
  • Regeneron Healthcare Solutions, Inc.$485
  • Sanofi$220
  • Novartis$182
  • plus $794 from 11 others

What the payments were for

  • Food & beverage$6,27597%
  • Education$1993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,474 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$98,687
Medicare patients
619
Services billed
1,653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa21$411,469
TremfyaGuselkumab24$315,009
Dupixent PenDupilumab55$202,519
Taltz AutoinjectorIxekizumab13$87,537
Dupixent SyringeDupilumab13$71,718
Doxycycline Ir-DrDoxycycline Monohydrate13$10,843
Metronidazole88$5,806
Ketoconazole212$4,149
Betamethasone Dipropionate134$4,044
Triamcinolone Acetonide320$2,610
Doxycycline Hyclate130$2,328
Doxycycline Monohydrate99$1,502
Azelaic Acid22$1,499
Clobetasol Propionate37$1,162
ValacyclovirValacyclovir Hcl47$1,150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$2,818$315,00924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Redlands

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →